KRAS and non-small cell lung carcinoma: Based on the effect of PCC0208027 on EGFR family members, we examined the growth inhibitory effect of PCC0208027 on different NSCLC cell lines, including EGFR-TKI-sensitive HCC827 cells, NCI-H1975 cells containing the EGFR T790M drug-resistant mutation, HER2-overexpressing Calu-3 cells, NCI-H1781 cells containing HER2 mutations and A549 cells with KRAS mutation21.